Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide in Right Ventricular Infarction
NCT00782652Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Mar 2006
- Primary completion
- Feb 2007
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in right ventricular infarction (RVMI) comparing Inhaled Nitric Oxide with Placebo (2 arms). Primary endpoint: Survival to hospital discharge or Day 30 without the need for renal replacement therapy or a Right Ventricular Assistance Device (RVAD). Started Mar 2006; status: terminated.
02
Drugs
nitric oxide
03
Conditions
right ventricular infarction (RVMI)
Beyond the preview
Go deeper on NCT00782652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782652.